The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed

Mark R Haussler, G Kerr Whitfield, C. A. Haussler, Jui-Cheng Hsieh, P. D. Thompson, S. H. Selznick, C. E. Dominguez, P. W. Jurutka

Research output: Contribution to journalArticle

1086 Citations (Scopus)

Abstract

The actions of 1,25(OH)2D3-VDR that have emerged from recent studies include, but clearly transcend, the bone and calcium/phosphate homeostasis effects originally attributed to vitamin D. This new understanding now encompasses many of the tissues formerly reported to contain vitamin D receptors, but for which no function of the vitamin-derived hormone could be ascribed. The insights gained from VDR knockout and allelic variation research confirm and extend these concepts, raising the prospect that, for the purpose of preventive measures, assessment of VDR polymorphisms may ultimately become part of a strategy to better identify and treat persons at risk for common disorders such as osteoporosis, breast cancer, or prostate cancer. We have learned much about VDR structure/function from natural mutations in 1,25-(OH)2D3-resistant patients and from site-directed mutagenesis experiments, as well as gained insight from the elucidation of analogous crystal structures for RAR, RXR, and TR. The next few years will no doubt witness a growing structural understanding of VDR, presumably culminating in the crystallographic resolution of physical details of liganded versus unliganded forms of VDR, perhaps in the absence and presence of various protein partners and/or VDRE binding sites. Such structural information should allow for the design of the next generation of synthetic analogs possessing the potential capability of selectivity controlling individual 1,25(OH)2D3 responses within the organism. Fundamental investigations also have led to an enhanced appreciation of the sequence of events in nuclear VDR signal transduction, offering promise that we may be able to understand how diverse 1,25(OH)2D3 agonists could differentially manipulate these steps in a promoter and/or tissue-specific fashion. Such analogs would therefore be endowed with therapeutic potential not only for classic VDR actions in calcium/phosphate homeostasis and bone mineralization, but also for hyperproliferative skin disorders and various types of cancer. A novel type of analog that will be useful in studies of VDR action is an authentic receptor antagonist, and preliminary reports((200,201)) indicate that this reagent may be available soon. Another new frontier of VDR function at the molecular level is clearly that of characterizing VDR-interacting proteins, and identifying how they mediate 1,25(OH)2D3 signaling within the context of specific gene promoters. These biochemical and genetic investigations may reveal mechanisms for potential interactions of 1,25(OH)2D3 with signaling pathways for other hormones, growth factors, and cytokines that physiologically modulate the wide array of vitamin D bioeffects.

Original languageEnglish (US)
Pages (from-to)325-349
Number of pages25
JournalJournal of Bone and Mineral Research
Volume13
Issue number3
DOIs
StatePublished - 1998

Fingerprint

Calcitriol Receptors
Vitamin D
Prostatic Neoplasms
Homeostasis
Hormones
Physiologic Calcification
Site-Directed Mutagenesis
Vitamins
Osteoporosis
Molecular Biology
Signal Transduction
Intercellular Signaling Peptides and Proteins
Proteins
Binding Sites
Breast Neoplasms
Cytokines
Bone and Bones
Skin
Mutation
Research

ASJC Scopus subject areas

  • Surgery

Cite this

The nuclear vitamin D receptor : Biological and molecular regulatory properties revealed. / Haussler, Mark R; Whitfield, G Kerr; Haussler, C. A.; Hsieh, Jui-Cheng; Thompson, P. D.; Selznick, S. H.; Dominguez, C. E.; Jurutka, P. W.

In: Journal of Bone and Mineral Research, Vol. 13, No. 3, 1998, p. 325-349.

Research output: Contribution to journalArticle

Haussler, Mark R ; Whitfield, G Kerr ; Haussler, C. A. ; Hsieh, Jui-Cheng ; Thompson, P. D. ; Selznick, S. H. ; Dominguez, C. E. ; Jurutka, P. W. / The nuclear vitamin D receptor : Biological and molecular regulatory properties revealed. In: Journal of Bone and Mineral Research. 1998 ; Vol. 13, No. 3. pp. 325-349.
@article{6958756d31ca45c69e8a09941e4f6e7d,
title = "The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed",
abstract = "The actions of 1,25(OH)2D3-VDR that have emerged from recent studies include, but clearly transcend, the bone and calcium/phosphate homeostasis effects originally attributed to vitamin D. This new understanding now encompasses many of the tissues formerly reported to contain vitamin D receptors, but for which no function of the vitamin-derived hormone could be ascribed. The insights gained from VDR knockout and allelic variation research confirm and extend these concepts, raising the prospect that, for the purpose of preventive measures, assessment of VDR polymorphisms may ultimately become part of a strategy to better identify and treat persons at risk for common disorders such as osteoporosis, breast cancer, or prostate cancer. We have learned much about VDR structure/function from natural mutations in 1,25-(OH)2D3-resistant patients and from site-directed mutagenesis experiments, as well as gained insight from the elucidation of analogous crystal structures for RAR, RXR, and TR. The next few years will no doubt witness a growing structural understanding of VDR, presumably culminating in the crystallographic resolution of physical details of liganded versus unliganded forms of VDR, perhaps in the absence and presence of various protein partners and/or VDRE binding sites. Such structural information should allow for the design of the next generation of synthetic analogs possessing the potential capability of selectivity controlling individual 1,25(OH)2D3 responses within the organism. Fundamental investigations also have led to an enhanced appreciation of the sequence of events in nuclear VDR signal transduction, offering promise that we may be able to understand how diverse 1,25(OH)2D3 agonists could differentially manipulate these steps in a promoter and/or tissue-specific fashion. Such analogs would therefore be endowed with therapeutic potential not only for classic VDR actions in calcium/phosphate homeostasis and bone mineralization, but also for hyperproliferative skin disorders and various types of cancer. A novel type of analog that will be useful in studies of VDR action is an authentic receptor antagonist, and preliminary reports((200,201)) indicate that this reagent may be available soon. Another new frontier of VDR function at the molecular level is clearly that of characterizing VDR-interacting proteins, and identifying how they mediate 1,25(OH)2D3 signaling within the context of specific gene promoters. These biochemical and genetic investigations may reveal mechanisms for potential interactions of 1,25(OH)2D3 with signaling pathways for other hormones, growth factors, and cytokines that physiologically modulate the wide array of vitamin D bioeffects.",
author = "Haussler, {Mark R} and Whitfield, {G Kerr} and Haussler, {C. A.} and Jui-Cheng Hsieh and Thompson, {P. D.} and Selznick, {S. H.} and Dominguez, {C. E.} and Jurutka, {P. W.}",
year = "1998",
doi = "10.1359/jbmr.1998.13.3.325",
language = "English (US)",
volume = "13",
pages = "325--349",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The nuclear vitamin D receptor

T2 - Biological and molecular regulatory properties revealed

AU - Haussler, Mark R

AU - Whitfield, G Kerr

AU - Haussler, C. A.

AU - Hsieh, Jui-Cheng

AU - Thompson, P. D.

AU - Selznick, S. H.

AU - Dominguez, C. E.

AU - Jurutka, P. W.

PY - 1998

Y1 - 1998

N2 - The actions of 1,25(OH)2D3-VDR that have emerged from recent studies include, but clearly transcend, the bone and calcium/phosphate homeostasis effects originally attributed to vitamin D. This new understanding now encompasses many of the tissues formerly reported to contain vitamin D receptors, but for which no function of the vitamin-derived hormone could be ascribed. The insights gained from VDR knockout and allelic variation research confirm and extend these concepts, raising the prospect that, for the purpose of preventive measures, assessment of VDR polymorphisms may ultimately become part of a strategy to better identify and treat persons at risk for common disorders such as osteoporosis, breast cancer, or prostate cancer. We have learned much about VDR structure/function from natural mutations in 1,25-(OH)2D3-resistant patients and from site-directed mutagenesis experiments, as well as gained insight from the elucidation of analogous crystal structures for RAR, RXR, and TR. The next few years will no doubt witness a growing structural understanding of VDR, presumably culminating in the crystallographic resolution of physical details of liganded versus unliganded forms of VDR, perhaps in the absence and presence of various protein partners and/or VDRE binding sites. Such structural information should allow for the design of the next generation of synthetic analogs possessing the potential capability of selectivity controlling individual 1,25(OH)2D3 responses within the organism. Fundamental investigations also have led to an enhanced appreciation of the sequence of events in nuclear VDR signal transduction, offering promise that we may be able to understand how diverse 1,25(OH)2D3 agonists could differentially manipulate these steps in a promoter and/or tissue-specific fashion. Such analogs would therefore be endowed with therapeutic potential not only for classic VDR actions in calcium/phosphate homeostasis and bone mineralization, but also for hyperproliferative skin disorders and various types of cancer. A novel type of analog that will be useful in studies of VDR action is an authentic receptor antagonist, and preliminary reports((200,201)) indicate that this reagent may be available soon. Another new frontier of VDR function at the molecular level is clearly that of characterizing VDR-interacting proteins, and identifying how they mediate 1,25(OH)2D3 signaling within the context of specific gene promoters. These biochemical and genetic investigations may reveal mechanisms for potential interactions of 1,25(OH)2D3 with signaling pathways for other hormones, growth factors, and cytokines that physiologically modulate the wide array of vitamin D bioeffects.

AB - The actions of 1,25(OH)2D3-VDR that have emerged from recent studies include, but clearly transcend, the bone and calcium/phosphate homeostasis effects originally attributed to vitamin D. This new understanding now encompasses many of the tissues formerly reported to contain vitamin D receptors, but for which no function of the vitamin-derived hormone could be ascribed. The insights gained from VDR knockout and allelic variation research confirm and extend these concepts, raising the prospect that, for the purpose of preventive measures, assessment of VDR polymorphisms may ultimately become part of a strategy to better identify and treat persons at risk for common disorders such as osteoporosis, breast cancer, or prostate cancer. We have learned much about VDR structure/function from natural mutations in 1,25-(OH)2D3-resistant patients and from site-directed mutagenesis experiments, as well as gained insight from the elucidation of analogous crystal structures for RAR, RXR, and TR. The next few years will no doubt witness a growing structural understanding of VDR, presumably culminating in the crystallographic resolution of physical details of liganded versus unliganded forms of VDR, perhaps in the absence and presence of various protein partners and/or VDRE binding sites. Such structural information should allow for the design of the next generation of synthetic analogs possessing the potential capability of selectivity controlling individual 1,25(OH)2D3 responses within the organism. Fundamental investigations also have led to an enhanced appreciation of the sequence of events in nuclear VDR signal transduction, offering promise that we may be able to understand how diverse 1,25(OH)2D3 agonists could differentially manipulate these steps in a promoter and/or tissue-specific fashion. Such analogs would therefore be endowed with therapeutic potential not only for classic VDR actions in calcium/phosphate homeostasis and bone mineralization, but also for hyperproliferative skin disorders and various types of cancer. A novel type of analog that will be useful in studies of VDR action is an authentic receptor antagonist, and preliminary reports((200,201)) indicate that this reagent may be available soon. Another new frontier of VDR function at the molecular level is clearly that of characterizing VDR-interacting proteins, and identifying how they mediate 1,25(OH)2D3 signaling within the context of specific gene promoters. These biochemical and genetic investigations may reveal mechanisms for potential interactions of 1,25(OH)2D3 with signaling pathways for other hormones, growth factors, and cytokines that physiologically modulate the wide array of vitamin D bioeffects.

UR - http://www.scopus.com/inward/record.url?scp=0031892913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031892913&partnerID=8YFLogxK

U2 - 10.1359/jbmr.1998.13.3.325

DO - 10.1359/jbmr.1998.13.3.325

M3 - Article

C2 - 9525333

AN - SCOPUS:0031892913

VL - 13

SP - 325

EP - 349

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 3

ER -